Find a local office
- This event has passed.
Prostate Cancer Programs & Services
Moving Forward with Improved Prostate Cancer Detection and Treatment — What’s at Stake Now?
Prostate cancer remains the second leading cause of cancer death among men in the U.S., with nearly 30,000 deaths annually. Deaths from prostate cancer have declined by about 40% since the advent of PSA screening in the late 1980s, and 40-70% of that decline may be attributable to screening. However, radiation therapy and surgery have a negative impact on quality of life.
Patterns of care in prostate cancer (PCa) have changed dramatically in the past 20 years, changing the way patients with this tumor present and how they are evaluated before and after diagnosis. Advances have been made in PCa imaging, biopsy methodology, in understanding causative factors and disease, in treatment-related quality of life, and in predicting the behavior of individual tumors using risk strata. Despite these advances, no consensus has emerged regarding the optimal treatment for the most common patient with PCa.
This two-day must-attend conference will cover the latest advancements in prostate cancer screening, detection and treatment, including:
- Current best practices in prevention and screening and treatment of PCa
- The most promising therapies, issues, and economic concerns in treatment
- Newly available therapies in 2016 and beyond
- Emerging treatment options
Featuring a Tour of the Cleveland Clinic’s Glickman Urological and Kidney Institute
Cleveland Clinic’s Glickman Urological and Kidney Institute is recognized worldwide for excellence in patient care, teaching and research.
The Glickman Urological and Kidney Institute merges Cleveland Clinic’s urology and nephrology programs. This consolidation of disciplines allows us to better serve patients in the prevention, diagnosis and treatment of kidney disease while we continue to provide high-quality patient care and carry on innovative research in all aspects of urology.
Urology and nephrology physicians and scientists at Cleveland Clinic are recognized worldwide for excellence in patient care, teaching and research. This year, U.S. News & World Report ranked both the urology program and our kidney disease program No. 2 in the nation.
“Prostate cancer is the second leading cause of cancer death in American men. One in seven men will be diagnosed with prostate cancer and 233,000 new cases are diagnosed annually”
- Interdisciplinary care of prostate cancer
- Evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of prostate cancer
- Essential elements to initiate and maintain a screening program
- Exploring recent risk assessment strategies for patients with newly diagnosed prostate cancer
- Comparing efficacy and safety data supporting various management options for localized prostate cancer, including radical prostatectomy, radiation therapy, brachytherapy, hormonal therapy, and active surveillance
- Examining evidence supporting several different treatment options for patients with advanced prostate cancer, including secondary hormonal therapy, chemotherapy, immunotherapy, and radioisotope therapy
- Assessing patients with prostate cancer for eligibility on promising clinical trials
- Current best practices in prevention and screening of PCa
- Promising therapies, issues, and economic concerns in the treatment of local disease
- Role of newly available therapies in 2016 and beyond
- Emerging treatment options for localized, advanced, and castration-resistant PCa
- Examining when to choose an Active Surveillance technique to improve quality of life of patients
- Examining the most up-to-date and effective prostate technologies to achieve more efficient workflow and improve patient care
- Advances in brachytherapy and evidence-based protocols
- Determining the appropriate treatment for low-risk patients
- • Advances in PCa imaging and biopsy methodology,
- • Understanding causative factors and disease to improve outcomes
- • Developing a comprehensive Prostate Cancer program as a center of excellence
- • Administrative aspects of operating an interdisciplinary Prostate Cancer program
- • Metrics, measures and outcomes of successful prostate cancer programs
The conference is ideally suited for physicians, nurses, administrators and other health professionals involved in prostate cancer – representing Community Hospitals, Health Systems, Academic Medical Centers, Hospital Networks, Medical Laboratories, and Research Institutions, including:
- Medical Oncologists
- Radiation Oncologists
- Surgeons
- Urologists
- Fellows, Nurse Practitioners, Nurses, Physician Assistants, Pharmacists, and other health care professionals may also be interested in participating
Boston Scientific
At Boston Scientific, we help you meet the challenges of constant change by delivering innovations across five urology subspecialties. With more than 40-years of experience, we are the global leader in the treatment of erectile dysfunction and male incontinence. Join us as we evolve the future of urology.
Website: www.bostonscientific.com
Janssen Oncology
At Janssen Oncology, we’re shaping the future of cancer treatment. And in the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health. We are part of Janssen Biotech, Inc., and the Janssen Pharmaceutical Companies of Johnson & Johnson.
Website: www.janssenbiotech.com/products/oncology
Bayer HealthCare
Bayer HealthCare is one of the world’s leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare provides products for General Medicine, Hematology, Neurology, Oncology and Women’s Healthcare.
Website: www.pharma.bayer.com
TOLMAR Pharmaceuticals
TOLMAR is deeply committed to its partnership with the urology community. Passion fueled the innovation, development, and advancement of ELIGARD® (leuprolide acetate for injectable suspension). TOLMAR is the inventor, developer, and manufacturer of all of the products in the ELIGARD family.
Website: www.eligard.com
Applied Radiology
Applied Radiology is a board-reviewed clinical journal reaching radiology professionals worldwide in print and digital formats since 1972. Editorially, Applied Radiology covers all aspects of diagnostic radiology, interventional techniques and therapeutic specialties.
Website: www.appliedradiology.com
AuntMinnie
AuntMinnie features the latest news and information about medical imaging and is a comprehensive community website for radiologists and related professionals in the medical imaging industry.
AuntMinnie provides a forum for radiologists, business managers, technologists, members of organized medicine, and industry to meet, transact, research, and collaborate on topics within the field of radiology with the ease and speed that only the Internet can provide.
Website: www.auntminnie.com
Cancer Network
Cancer Network is an online resource that offers a wide range of news, information, and educational content geared toward oncology professionals. It is also home of the journal ONCOLOGY, which provides review articles and other features written by experts in the field that focus on practical issues in oncology. Cancer Network and ONCOLOGY are published by UBM Medica, one of the largest healthcare media and publishing companies in the U.S., serving the information needs of decision makers who cover the patient care spectrum.
Website: www.cancernetwork.com
Imaging Technology News
As “The Trusted Resource for Emerging Technology and Clinical Applications in Medical Imaging and Radiation Oncology,” Imaging Technology News (ITN) showcases the latest, most innovative diagnostic & therapeutic technologies and service solutions. ITN is edited for professionals in radiology/medical imaging, therapeutic radiology, business administration and IT in hospitals, freestanding imaging and radiation oncology centers and purchasing organizations. Features include Comparison Charts, Technology Overviews, Advances In, Business & Economics, Case Studies and more.
Website: www.itnonline.com
Men’s Health Network
Men’s Health Network (MHN) is a national non-profit organization whose mission is to reach men and their families where they live, work, play, and pray with health prevention messages and tools, screening programs, educational materials, advocacy opportunities, and patient navigation. MHN is committed to improving the health and well-being of men and their families. The goals of the Network are as follows:
- to save men’s lives by reducing the premature mortality of men and boys;
- to foster health care education and services that implement positive lifestyle decisions for men of all ages, and their families;
- to increase the physical and mental health of men so that they can live fuller and happier lives.
Website: www.menshealthnetwork.org